# Sintx Technologies, Inc.: overview SINT · Nasdaq · CIK 1269026 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sint.md) · [Financials](/companies/sint/financials.md) · [Filings](/companies/sint/filings.md) · [Insiders](/companies/sint/insiders.md) Latest reported revenue: [$452.0k](/filings/0001493152-26-037116.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037116). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [799](/filings/0001493152-25-021930.md) | [542 d](/filings/0001493152-26-011924.md) | [369](/filings/0001493152-26-023919.md) | [151](/filings/0001493152-26-037116.md) | [208](/filings/0001493152-25-021930.md) | [290 d](/filings/0001493152-26-011924.md) | [380](/filings/0001493152-26-023919.md) | [452](/filings/0001493152-26-037116.md) | | Gross margin | % | [73.7%](/filings/0001493152-25-021930.md) | [71.6% d](/filings/0001493152-26-011924.md) | [33.3%](/filings/0001493152-26-023919.md) | [37.7%](/filings/0001493152-26-037116.md) | [44.7%](/filings/0001493152-25-021930.md) | [64.8% d](/filings/0001493152-26-011924.md) | [37.9%](/filings/0001493152-26-023919.md) | [61.5%](/filings/0001493152-26-037116.md) | | Operating margin | % | [(802.0%)](/filings/0001493152-25-021930.md) | [(319.6%) d](/filings/0001493152-26-011924.md) | [(645.8%)](/filings/0001493152-26-023919.md) | [(1764.9%)](/filings/0001493152-26-037116.md) | [(1613.0%)](/filings/0001493152-25-021930.md) | [(799.3%) d](/filings/0001493152-26-011924.md) | [(843.9%)](/filings/0001493152-26-023919.md) | [(638.9%)](/filings/0001493152-26-037116.md) | | Net margin | % | [(780.9%)](/filings/0001493152-25-021930.md) | [(312.7%) d](/filings/0001493152-26-011924.md) | [(621.1%)](/filings/0001493152-26-037116.md) | [(1535.1%)](/filings/0001493152-26-037116.md) | [(1701.4%)](/filings/0001493152-25-021930.md) | [(763.8%) d](/filings/0001493152-26-011924.md) | [(742.4%)](/filings/0001493152-26-037116.md) | [(598.7%)](/filings/0001493152-26-037116.md) | | Diluted EPS | $ per share | [(6.96)](/filings/0001493152-25-021930.md) | not reported | [(1.29)](/filings/0001493152-26-023919.md) | [(0.91)](/filings/0001493152-26-037116.md) | [(3.46)](/filings/0001493152-25-021930.md) | not reported | [(0.70)](/filings/0001493152-26-023919.md) | [(0.75)](/filings/0001493152-26-037116.md) | | Free cash flow | $k | [(2,581) d](/filings/0001493152-25-021930.md) | [(1,270) d](/filings/0001493152-26-011924.md) | [(1,360)](/filings/0001493152-26-023919.md) | [(2,409) d](/filings/0001493152-26-037116.md) | [(2,601) d](/filings/0001493152-25-021930.md) | [(2,386) d](/filings/0001493152-26-011924.md) | [(2,498)](/filings/0001493152-26-023919.md) | [(2,851) d](/filings/0001493152-26-037116.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.6](/filings/0001493152-23-009492.md) | [1.6](/filings/0001493152-24-011546.md) | [2.6](/filings/0001493152-25-010870.md) | [2.9](/filings/0001493152-26-011924.md) | [1.0](/filings/0001493152-26-011924.md) | | Gross margin | % | [25.9%](/filings/0001493152-23-009492.md) | [83.0%](/filings/0001493152-24-011546.md) | [70.2%](/filings/0001493152-25-010870.md) | [71.9%](/filings/0001493152-26-011924.md) | [45.3%](/filings/0001493152-26-011924.md) | | Operating margin | % | [(1752.5%)](/filings/0001493152-23-009492.md) | [(726.1%)](/filings/0001493152-24-011546.md) | [(508.5%)](/filings/0001493152-25-010870.md) | [(486.6%)](/filings/0001493152-26-011924.md) | [(1053.1%)](/filings/0001493152-26-011924.md) | | Net margin | % | [(1536.1%)](/filings/0001493152-23-009492.md) | [(771.2%)](/filings/0001493152-24-011546.md) | [(314.4%)](/filings/0001493152-25-010870.md) | [(381.8%)](/filings/0001493152-26-011924.md) | [(1018.1%)](/filings/0001493152-26-011924.md) | | Diluted EPS | $ per share | [(39.91)](/filings/0001493152-23-009492.md) | [(60.81)](/filings/0001493152-24-011546.md) | [(624.47)](/filings/0001493152-25-010870.md) | [(15.19)](/filings/0001493152-26-011924.md) | [(6.16)](/filings/0001493152-26-011924.md) | | Free cash flow | $m | [(13.9)](/filings/0001493152-23-009492.md) | [(11.7)](/filings/0001493152-24-011546.md) | [(14.6)](/filings/0001493152-25-010870.md) | [(9.3)](/filings/0001493152-26-011924.md) | [(8.8)](/filings/0001493152-26-011924.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sint/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $978.0k | 523,013 | | New +523,013 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $332.5k | 209,205 | | New +209,205 | | [Veracity Capital LLC](/funds/1811005.md) | 2026-06-30 | $143.4k | 76,674 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $59.7k | 31,930 | | New +31,930 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $56.3k | 30,101 | | Reduced −2,043 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $44.0k | 23,531 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $39.1k | 20,905 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $24.9k | 13,302 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $22.3k | 11,921 | | Added +6,968 | | [Virtus Wealth Solutions LLC](/funds/2045870.md) | 2026-06-30 | $18.7k | 10,000 | | Unchanged | ## Recent filings [All 642 filings](/companies/sint/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 16:05 ET | [DEF 14A](/filings/0001493152-26-049429.md) | Proxy statement, period 2026-10-30 | 0001493152-26-049429 | | 2026-10-09 | 17:00 ET | [8-K](/filings/0001493152-26-046576.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-046576 | | 2026-10-01 | 09:05 ET | [8-K](/filings/0001493152-26-045278.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-045278 | | 2026-08-13 | 09:05 ET | [8-K](/filings/0001493152-26-037613.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-037613 | | 2026-08-11 | 16:10 ET | [8-K](/filings/0001493152-26-037130.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-037130 | | 2026-08-11 | 16:05 ET | [10-Q](/filings/0001493152-26-037116.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037116 | | 2026-07-23 | 09:05 ET | [8-K](/filings/0001493152-26-034343.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-034343 | | 2026-07-02 | 17:00 ET | [8-K](/filings/0001493152-26-031949.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-031949 | | 2026-06-03 | 09:30 ET | [8-K](/filings/0001493152-26-026985.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-026985 | | 2026-05-27 | 15:00 ET | [8-K](/filings/0001493152-26-025377.md) | 3.01 Delisting notice | 0001493152-26-025377 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-011924.md), filed Mar 20, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1269026 - Tickers: SINT - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:10 ET. No prices; not investment advice.